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Nitric oxide generating/releasing materials

Harnessing the impressive therapeutic potential of nitric oxide (NO) remains an
ongoing challenge. This paper describes several of the current strategies both with
respect to the underlying chemistry and physics and to the applications where
they have shown promise. Included in this overview are molecular systems such as
NONOates that release NO through chemical reactions and delivery vehicles such
as nanoparticles that can generate, store, transport and deliver NO and related
bioactive forms of NO such as nitrosothiols. Although there has been much positive
movement, it is clear that we are only at the early stages of knowing how to precisely
produce, transport and deliver to targeted sites therapeutic levels of NO and related
molecules.
Keywords: liposomes • nanoparticles • nitrosothiols • NO • NONOates

Nitric oxide (NO) is a free radical that is
naturally produced in mammals. It has been
well known to play a key role in a wide variety of physiological and pathophysiological
important processes, such as neurotransmission, neuronal communication, platelet adhesion, thrombosis, vasodilation, inflammation
and wound healing [1] . Over the past two
decades, countless research has been conducted to develop most effective NO-generating and NO-releasing materials for clinical
therapies. A great number of synthetic compounds (e.g., N-diazeniumdiolates, nitrosothiols, nitrosohydroxylamines and nitrosyl
metal complexes) have been developed to
chemically stabilize and release NO in a controlled manner, and have been exploited in
many biomedical applications. The translation of the therapeutic potential of NO to
bedside has been slowed down by its short
biological lifetime, instability during storage
and potential toxicity. A promising strategy
for addressing these limitations and thus
increasing the targeted NO release is developing NO-delivery devices/vehicles based on
nanotechnology.
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NO donors
Nitrate/nitrite/nitroso compounds

Organic nitrates and nitrites are the NO
donor drugs currently in use to treat coronary artery disease. Nitroglycerin (glyceryl
trinitrate), isosorbide dinitrate, isosorbide
mononitrate and isoamyl nitrite are the
examples of this class (Figure 1A) . These
products release NO on exposure to certain
endogenous enzymes [2] . Extended use of
nitrate vasodilators induce nitrate tolerance
leading to tachyphylaxis as well as aggressive side effects including increased oxidative
stress, endothelial dysfunction and cardiac
autonomic dysfunction [1,3] . The tolerance
is dependent on the type of nitrate and dosing schedule [4] . Slow release forms of isosorbide mononitrate and dinitrate have been
formulated to reduce nitrate tolerance [5] .
Supplementing the nitrate treatment with
antioxidants seems to reduce the oxidative
stress-induced damage [3,6–8] .
Sodium nitroprusside (SNP) is another
NO-based drug that is in use for vasodilation in emergency setting to treat acute
hypertension [9] . SNP is a rapid vasodilator
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Figure 1. Nitric oxde donor drugs. (A) Some nitrates/nitrite/nitroso products. Glyceryl trinitrate, isoamyl
nitrite. Isosorbide mononitrate, sodium nitroprusside. (B) Some diazeniumdiolates. Diethylamine/NO V-PYRRO/
NO. Spermine/NO. (C) Some S-nitrosothiols. S-nitrosoglutathione; S-nitroso-N-acetylcysteine; S-nitrosoacetylpenicillamine.
NO: Nitric oxide.

with a very short half life, needing rapid titration. The
major complications of SNP therapy are hypotension,
and toxicity from accumulation of cyanide, usually
in patients with renal insufficiency, when treated for
more than 24 h [10,11] .
N-diazeniumdiolates

Diazeniumdiolates (NONOates) are another class of
NO donors that are getting great attention recently
for the ease of preparation and generating predictable
amounts of NO from these products [2,12] . NONOates carry an [N(O-)N=O] group on a nucleophile
adduct, usually an amine (Figure 1B) [13,14] . NONOates decompose spontaneously in solution at physiological pH and temperature to generate NO. The rate
of decomposition is solely dependent on the structure
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of the nucleophile, pH and temperature of the medium
and not influenced by reducing agents or biological tissue [12,14] . The biological activity of these products correlate with the amount of NO released [14] . By structural manipulations, NONOates can be designed for
targeted delivery of NO [2,12,15–16] and conjugate other
therapeutic molecules to enhance their therapeutic
potential [2,17–18] . Since the NO release from NONOates is not influenced by biological factors, these
products do not develop tolerance [19] .
The biological activity of NONOates has been
tested in various experimental models such as vasospasm, pulmonary hypertension, platelet adhesion/
aggregation, with promising results [2,12,20] . Saavedra et al. [15] designed a prodrug V-PYRRO/NO for
targeted delivery of NO to liver. This drug releases
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NO only after being processed by CYP450. The same
group also developed another NONOate prodrug
that would release NO only following esterase activity
within cells, causing apoptosis of the human leukemia
cell lines studied [21] . Tang et al., [16] coupled PYRRO/
NO to a chain of amino acids recognized to be a substrate for prostate-specific antigen, which is upregulated within prostate cancer metastases. Conjugation
of antitumor agent, 5-fluorouracil, to an NONOate
enhanced the cytotoxicity effect of the conjugate on
cancer cells [17] .
NONOates have also been tested in human subjects. Inhaled DETA/NO reduced pulmonary vascular
resistance without affecting the systemic blood pressure or cardiac output in patients with acute respiratory
distress syndrome [22,23] .
At present, NONOates are not yet approved for
clinical use. However, the possibility of modulation of
structure to control NO release as well as for targeted
delivery, enabling tagging other therapeutic molecules
and lack of tolerance make NONOates potential candidates for therapeutic use. The toxicity of NONOates
has not yet been fully established. Accumulation of
amines and their metabolites released from NONOates can induce cytotoxicity [12,20] . More detailed
studies are needed to establish long-term safety of
these products.
S-nitrosothiols

S-nitrosothiols (RSNOs) are adducts of R-SH and NO
and considered as excellent source of NO (Figure 1C) .
The rate of NO release from RSNOs is influenced
by various factors, metal ions, reducing agents and
enzymes, light, heat and pH [2,24] . Endogenous RSNOs
such as S-nitrosoglutathione (GSNO) are distributed
in red blood cells, plasma and tissue at different concentrations [2,25] . RSNO-based therapeutics exhibit
physiologic effects very similar to other NO-related
therapeutics [24,26–28] . RSNOs have also been tested in
humans as therapeutics for different clinical conditions
with promising results [2] .
RSNO-based therapeutics can be considered more
efficient than NO-based therapeutics due to their
capacity for long lasting release of NO as well as a more
facile transnitrosating capability. SNO-based NO
donors have been shown to induce vasodilation longer
than other types of NO donors tested [29,30] . Lipophilic
S-nitrosothiols induced vasodilation even longer than
conventional S-nitrosothiols [2] .
Since the NO release from RSNOs depend on various physiological conditions and does not depend on a
specific mechanism like nitrate, these products do not
induce tolerance on long-term use [2,31–33] . The long
lasting biological effects of RSNOs demonstrated in
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preclinical trials make them potential therapeutics for
NO-/SNO-based drugs. The recent findings on the
role of S-nitrosothiols in various biological processes
promote further the exploration/urge of developing
RSNO-based drugs.
Vehicles for NO donors
Gold nanoparticles

Gold nanoparticles (GNP) are nontoxic, biocompatible and stable. The particles can be synthesized with
desired size (2–250 nm) and surface functional groups
for the conjugation of therapeutic products. These features made the particles versatile carriers of molecules
for biological applications. GNP have been developed
as vehicles for drugs and gene delivery as well as for
imaging [34–36] .
The synthesis of GNP involves the reduction of
tetrachloroaurate (AuCl4-) with sodium citrate or
sodium borohydride and in the presence of a stabilization agent (Figure 2) . The chemistry of the stabilizing
agent determines the surface properties and functionality of the particles. Citrate-capped particles carry
negative charge on the surface and are taken up by cells
easily [35] . GNP have great affinity for thiol ligands.
The use of an alkanethiol as a stabilizing agent yields
nanoparticles stabilized by a surface monolayer of alkanethiols [34] . These monolayer-protected clusters of
GNP can be used as basic blocks for the preparation of
vehicles to carry desired molecules for bioapplications.
Using suitable bifunctional alkanethiols the functionality of the monolayer can be changed through a substitution reaction to conjugate molecules of interest on
the surface of the GNP [34] .
Surface coating of GNP with amines is the most
widely used technique for the generation of delivery
vehicles [34–36] . Amine groups can be readily derivatized by different chemistry for the conjugation of
therapeutic molecules. Amine-coated GNP have been
directly used for gene delivery without further modification. Amines are positively charged at physiological
pH and therefore can bind negatively charged nucleic
acids. Amine-coated GNP were able to bind DNA plasmids and delivered to 293T cells much more efficiently
than the commonly used cationic polymer transfection
agent polyethylenimine [35] .
Rothrock et al. [37] developed N-diazeniumdiolatebased NO-releasing GNP using amine-carrying GNP.
The release rate and total amount of NO released from
N-diazeniumdiolate were controllable by varying the
number and/or chemical structure of the amine agent
used in the synthesis of the particles. RSNO-based
NO-releasing GNP have been prepared by simply
mixing borohydride-reduced GNP with RSNOs [38] .
SNAP-GNP were taken up by human hepatic stel-
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Figure 2. Synthesis of gold nanoparticles. HAuCl4 is reduced by sodium borohydride in the presence of a stabilization agent, a thiol
(-SH) ligand. The thiol ligand is exchanged by another thiol reagent carrying a desired functional group (x) that can be derivatized
into a final product (y).

late cells without inducing any toxicity. These GNP
reduced the cell proliferation and tube formation,
indicating potential therapeutic use of the particles
for chronic liver disease. Sudhesh et al. [39] prepared
nitrobenzimidazole-capped GNP as a potential cancer therapeutic. The cytotoxic effect of these GNP on
cervical cancer cell lines was much higher in the presence of light than in the absence indicating the role of
released NO in the effect.
The biocompatibility of GNP is highly dependent
on the stabilizing agents coated on the surface of GNP.
Citrate-treated GNP have been shown to release NO
from RSNOs in vitro as well as from serum samples [40] .
The NO production from RSNOs was inhibited by
coating GNP with glutathione. This property of GNP
has been considered as a potential to induce oxidative
stress and cytotoxicity in biological applications [40,41] .
Amine-coated GNP can be cytotoxic due to the positive charge. Efforts are being made to generate more
biocompatible GNP by derivatizing the surface amines
to acetamides or hydroxyl groups [42] .
Silica nanoparticles

Sol–gel-derived materials serve as excellent carriers of
molecules due to their porous structures. Sol–gel technology has been applied in biomedical applications,
delivery of therapeutic drugs, development of biosensors
and stationary phases for chromatography, biophysical
studies to evaluate protein dynamics, protein–ligand
interactions and protein–protein interactions [43,44] .
The encapsulation of delicate biomolecules such as
enzymes, antibodies and even whole cells could be
safely trapped within sol–gel glasses. They retain their
bioactivity and are protected by the silica cage [45,46] .
The sol–gels are usually prepared from inorganic
metal salts or metal organic compounds such as
metal alkoxides. The most commonly made sol–gels
are silica sol–gels. Silica nanoparticles (SiNP) developed from these sol–gels are considered as stable,
nontoxic and biocompatible for delivering bioactive
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molecules [47,48] . Typically, SiNP are made from alkoxysilanes. Derivatives of silanes with different functional groups such as amines and thiols are commercially available. While the porous sol–gels made from
alkoxysilanes alone are useful to simply load biomolecules into the pores, the derivatives of silanes offer
multiple applications. The functional groups can be
used to conjugate biomolecules to SiNP, which may
not be efficiently retained by the porous structures of
sol–gels. In addition, target molecules can be attached
to the surface of particles for site-specific drug delivery. Polyethylene glycol chains may be surface coated
to enhance the circulation life of SiNP.
In the recent years, SiNP have been developed for
the delivery of NO from different NO donors such as
nitrite, RSNOs and NONOates. An interesting variation on the silica particles is a hybrid nanoparticle platform [49] that has been shown to be highly effective for
both topical [50–54] and systemic applications [47,55–56] .
The use of the term hybrid refers to a combination
of the standard silane-derived hydrogel with a strong
amorphous hydrogen bonding network that confers a
‘glassy’ quality to the platform. The platform evolved
out of the finding that nitrite could be converted to
NO within sugar-derived glassy matrices through a
solid state redox process that likely involves the formation of N2O3. The NO-containing glass rapidly
dissolves upon contact with water releasing a burst of
NO. The hybrid platform sought to use the hydrogel to
provide a robust matrix and incorporate glassy (strong
hydrogen bonding networks) elements that would
allow for the solid state conversion of nitrite to NO
and slow the release of NO. The resulting platform
which uses chitosan to provide the internal ‘glassy’
element and thereby plug the pores of the hydrogel
spontaneously forms nanoparticles that release NO in
a slow sustained manner when the nanoparticles are
exposed to moisture. Release rates of NO can easily be
tuned through straightforward variation of the initial
composition of the nanoparticles. More recently this
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platform has been used for systemic slow delivery of
S-nitrosothiols [30] .
NO-SiNP exhibited bactericidal activity in skin
infections against drug-resistant bacteria (Staphylococcus aureus), promoted wound healing and reduced
abscesses in murine models [54,57] . NO-SiNP also
induced vasodilatory effects in various animal models [47,55–56] . However, NAC-SNO-SiNP induced
longer vasodilatory effects than NO-SiNP in hamsters [30] . RSNOs are known to induce long-lasting
vascular effects due to their capability of transnitrosation. NONOates-SiNP also exhibited antimicrobial activity as well as anticancer activity [48] .
These results suggest that SiNP carrying NO donors
may be useful for various NO-based therapeutic
applications.
Polymeric vehicles
Biocompatible polymer microparticles and nanoparticles have been used frequently as drug delivery vehicles
due to their bioavailability, encapsulation capability,
controlled release and low toxic properties [58] . Such
polymers include PEG, polyurethane (PU), PMMA,
poly(vinyl pyrrolidone) (PVP), poly(amidoamine),
poly(ethylene oxide), poly(propylene oxide), poly(vinyl
chloride), polylactic acid, polyglycolic acid and polylactic-co-glycolic acid. The NO donors can be incorporated into or chemically linked to biopolymers in order
to mimic the endogenous NO production directly at
the target site.
Polymers

In the 1990s, Smith and coworkers [59] first successfully developed NO-releasing polyethyleneimine
microspheres with NONOates as NO donors. They
outlined three general polymer types (Figure 3) containing the NONOates. There is a wide range of control over the kinetics of NO release in these materials by varying the organic monomers used to prepare
the polymers, which make them very promising
candidates for therapeutic applications. Since then,
research has focused on the preparation of new NOreleasing polymers and the application of these materials to biomedical devices. Here, the recent research
on the polymer-based NO-releasing and -generating
materials is discussed.
Polyurethanes are used as vascular substitutes. The
enhanced blood compatibility of PU makes them
particularly interesting in the scope of NO-releasing
materials. Incorporation of a NONOate-tagged peptide into PU improved the thromboresistance of this
polymer [60] . NONOate moieties can also be generated directly on the polymer chain of PU carrying
secondary amines [61] . A new method of incorpora-
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tion of methoxymethyl- or sugar-protected preformed
NONOate moieties directly into chain extender
diols, which are then incorporated into the PU backbone provided the ability to control the number of
NONOate groups incorporated into the polymer
backbone [62] .
RSNOs have also been used as NO donors in numerous polymeric materials to form hydrogels and blended
solid films [63,64] . GSNO-loaded solid films [58] of
PVA/PVP blends stabilized GSNO and the films were
capable of releasing both NO and GSNO to aqueous
solution through diffusion. In another study [59] , the
authors covalently attached SNO groups to the polymer backbone, through the condensation reaction of
diols (ethylene glycol and PEG) with mercaptosuccinic
acid, followed by the S-nitrosation of the SH groups by
a gaseous NO/O2 mixture. The polynitrosated polyesters provided sustained NO release for more than 20 h
at physiological temperature.
DeRosa and coworkers [65] developed a new group
of plastics that release NO. The NONOate derivatives of polyacrylonitrile have a duration of NO release
>80 days. These NONOate-acrylonitrile-based polymers are stable at room temperature for many months
and may thus represent a broad class of commercially
viable materials to be developed as NO donors.
Dendrimers

Dendrimers are monodisperse macromolecules with
a tridimensional structure that is highly ramificated
and regular around the nucleus. Stasko and Schoenfisch [66] prepared the NO release polypropylenimine
dendrimers by generating NONOates on different
amines. Secondary amine dendrimer conjugates
exhibited high storage capacity for NO and released
NO for longer periods than small molecule secondary amine NONOates. The authors further [67]
synthesized two generation 4 poly(amidoamine)
dendrimers with S-nitrosothiol exteriors and characterized their ability to inhibit thrombin-mediated
platelet aggregation. Recently, Johnson et al. [68]
developed a dendrimer with SNAP as NO donor.
The NO release was initiated by glutathione. This
system successfully reduced ischemia/reperfusion
injury in an isolated, perfused rat heart with optimal
therapeutic dose of NO donor under physiological
glutathione concentrations.
Micelles

Polymeric micelles are generally lower in size than
nanoparticles and liposomes and larger than dendrimers, while sufficiently small to penetrate tissues.
Jo and coworkers [69] designed block copolymer proamphiphiles and amphiphiles for providing long-
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Figure 3. Three different approaches used to incorporate nitric oxide donors within polymer materials. NONOate
groups are noncovalently dispersed within the (A) polymer matrix, (B) covalently bound to pendent polymer side
chains, (C) covalently bound directly to the polymer backbone.
NO: Nitric oxide.

term NO release. They suggested that the creation
of a hydrophobic microenvironment within a micelle
core could protect a NONOate from proton-catalyzed NO liberation. The hydrophobic core of the
micelle shielded the NONOate from water, and thus
protons, delaying NO release to a remarkable 7-day
half life. Kanayama et al. [70] prepared PEGylated
polymer micelles containing 4-nitro-3-trifluoromethylphenyl units as NO donors within the core.
These micelles were capable of delivering exogenous
NO into tumor cells in a photo controlled manner. Doung et al. [71] conjugated GSNO to copolymer backbone and used micellization approach to
yield NO-polymeric nanoparticles. These polymeric
nanoparticles substantially improved NO stability
in aqueous media without affecting the efficacy of
intracellular delivery.
The combined use of NO donors with polymeric
matrices may not only favor a more controlled administration of the donor, but also regulate NO cellular effects. Sorragi et al. [72] found that PVA and
PVP polymer solutions reduced the cytotoxicity and
enhanced the antiproliferative effects of GSNO in
smooth muscle cell cultures.
Lipid-based nanocarriers

Liposomes are vesicles formed by an aqueous core
surrounded by one or several lipid bilayers (Figure 4) .
Hydrophilic drugs can be incorporated into the inner
aqueous cavity, while lipophilic drugs may be incorporated into the bilayer. Recently, liposomes have been
used for carrying and delivering NO in various biomedical applications [73] . Huang et al. [74] developed
a bioactive gas-delivery method, using echogenic liposomes as the NO carrier, to inhibit intimal hyperplasia. The cationic liposomes provide the highest NO
delivery and incorporation into cells, with rapid NO
release in the first 0.5 h, followed by slow NO release
for the next several hours. RSNOs [75] and NONOates [76] have also been encapsulated into lipid vesicles.
The basic intraliposomal environment dramatically
delayed spontaneous NO release.
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Recently, a prominent NO donor [Ru(terpy)(bdqi)
NO](PF6)3 has been synthesized and bound to lipid
carriers for topical administration [77] . The potential for
delivering NO in therapeutic quantities is tenable since
the nitrosyl ruthenium complex must first reach the
‘target tissue’ and then release the NO upon stimulus.
Perera and coworkers [78] encapsulated nitric oxide synthase (NOS) enzymes within 1,2-distearoyl-glycero3-phosphocholine with an encapsulation efficiency
of about 25–40%. The NOS-loaded liposomes were
stable for 15 days, during which the NOS-enzymatic
activity was also retained. Ostrowski et al. [79] demonstrated that the photochemical NO precursors
CrONO and mac-CrONO can be encapsulated into
stable phosphatidylcholine liposomes and that photoly
sis of these in solution is an effective method for delivering NO. The liposomes provide a means to maintain a localized high concentration of NO-releasing
complexes and are easily modified for in vivo targeting
through self assembly.
Safety & feasibility
The presented platforms all offer various benefits supported by several levels of evidence. From a translational
standpoint, safety and practicality are the two greatest
challenges. Even the clinically available NO-generating
compounds, such as the organic nitrites/nitrates, have
some limitations. Organic nitrates only release NO in
tissues expressing the enzyme mitochondrial aldehyde
dehydrogenase 2; however, this enzyme is irreversibly inactivated with use thus resulting in the emergence of tachyphylaxis (also known as nitrite/nitrate
tolerance), thereby limiting the utility of this class of
materials. Furthermore, continued use has been shown
to upregulate PDE5, resulting in increased vasoconstriction; the complete opposite of the desired clinical
outcome [80–82] .
NONOate-associated toxicity is a topic of great concern, and a stimulus for modification. For example,
V-PYRRO/NO has the potential to be converted to
N-nitrosopyrrolidine, an extraordinarily potent experimental hepatocarcinogen [83] . In order to reduce the
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risk of the toxic metabolites, several groups have created NONOates bound to large immobile structures
and nanoparticles. Sol–gel-based coatings which integrate N-(6-aminohexyl) aminopropyltrimethoxysilane can be loaded with NONOates. When the NO
molecules are subsequently released, the metabolites
remain bound to the sol–gel coating. However, even
with the application of a surface coating, the N-nitroso
groups are still cytotoxic to adjacent fibroblast cells at
antimicrobial concentrations (40%) [84] .
The utility of prepared S-nitrosothiols has limitations because thiols spontaneously form disulfide
bonds in the presence of water and heat. Thus most
S-nitrosothiols must be kept refrigerated as dry powder until they are mixed and administered, limiting
translational applications [27] .
Therefore, it is clear that successful utilization of
an NO-donating agent will not only be based on the
properties of the chemical compound itself, but that
of the delivery vehicle and storage approach. As listed
above, nanotechnology represents one such approach,
but further innovation is needed to fully capitalize on
the multifaceted benefits of NO therapy.
NO delivery via nanoparticles raises the added
safety issue associated with the nanoparticles themselves. Most of the toxicity studies to date relating
to NO delivery involve the silane- or silica-derived
nanoparticles. No major toxicity has been observed
to date. For the hybrid hydrogel nanoparticles both
topical and systemic studies have been conducted.
Topically applied hybrid hydrogel nanoparticles
were shown not to cause any detectable inflammatory response in the surrounding skin in a rat
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model [85] . Systemically administered hybrid hydrogel NO-releasing nanoparticles were shown to be
anti-inflammatory in a hamster model [47] . More
recently, these nanoparticles were evaluated using a
zebra fish embryo toxicity model [86,87] . The study
[Harper SL, Unpublished Data] revealed no evidence of
toxicity. Most recently, as part of large animal study
(pig) examining the efficacy of these nanoparticles to
prevent and treat hemorrhagic shock, organ histology
showed no evidence of damage due to the nanoparticles including a detailed histological examination of kidney [Cabrales P, Unpublished Data] . Overall
the emerging picture is one in which silane-derived
nanoparticles are nontoxic. The exact mechanism of
elimination for both topically applied nanoparticles
and systemically applied nanoparticles still needs to
be explored.
Conclusion & Future perspective
The results to date indicate that the above-described
NO delivery platforms have the potential to impact
both topical and systemic clinical applications.
Potential topical applications include uses that cover
enhanced rates of wound healing and treatment of a
wide variety of topical infections by most pathogens
including ESKAPE organisms, fungus and parasites
such as those associated with cutaneous leishmaniasis. The ability of some nanoparticle formulations
to penetrate skin and release NO in a slow sustained
manner opens the door for a topical treatment of erectile dysfunction. Systemic applications could include
treatment of vascular inflammatory conditions arising
from hemorrhage, hemoglobinopathies, hemolytic dis-

Conjugated antibody on surface can target lipsome

Water soluble drugs incorporated
into the inner aqueous cavity

Water insoluble drugs incorporated
into the lipid bilayer

Figure 4. Liposome structure.
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orders and diseases caused by NO-sensitive organisms
such as Chagas disease and African sleeping sickness.
In all cases, the dosing and timing will prove critical
since an inflammatory cascade once fully underway
is fed by NO generated by macrophages. The emerging picture is one in which NO delivered at an early
enough stage within the vasculature can short circuit
the inflammatory cascade.
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Executive summary
• Harnessing the therapeutic potential of nitric oxide and related bioactive forms of nitric oxide such as
S-nitrosothiols and nitrite is a challenging but important biomedical objective.
• Controlled targeted nitric oxide delivery is therapeutically desirable for both systemic and topical applications.
• There are several promising strategies that are currently being developed and tested.
• Promising approaches include nanoparticle delivery platforms that can ultimately result in both controlled
delivery and tissue-specific targeting.
• Toxicity and pharmacokinetic studies are still required before clinical translation is fully possible.
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